Evidence map›Paper›PMID 27744456›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2016

Characterization and Bioavailability of Wogonin by Different Administration Routes in Beagles.

Na Zhu, Jian-Chun Li, Jin-Xiu Zhu, Xiu Wang, Jin Zhang

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Flavone-Rich Fractions and Extracts fromMolecules (Basel, Switzerland) · 2021
    Article
  8. The Therapeutic Potential of Wogonin Observed in Preclinical Studies.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Na ZhuFaculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China (mainland).
Jian-Chun LiFaculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China (mainland).
Jin-Xiu ZhuDepartment of Pharmacy, The 1st Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China (mainland).
Xiu WangFaculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China (mainland).
Jin ZhangFaculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, China (mainland).
Bengbu Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND With the gradually accumulating research on pharmacological activity of wogonin, the in vitro analysis research on wogonin has become more and more popular, but there are very few reports about in vivo detection, and there are no solid dispersions (SDs) of Wogonin. The aim of this study was to explore the formation of solid dispersions (SDs) of wogonin. The reasons for the low bioavailability were studied through different routes of administration. MATERIAL AND METHODS SDs was formulated using the solvent evaporation method via polyvinylpyrrolidone K30 (PVP). The characterization of the drug and its carrier was detected by X-ray diffraction (XRD) and differential scanning calorimetry (DSC). The serum concentrations of Wogonin were detected using the LC-MS/MS method. Six beagles were fed 3 different formulations of wogonin in 3 cycles. RESULTS The SDs of wogonin had a higher solubility than the physical mixtures. Based on XRD and DSC, wogonin was transformed from a crystalline morphology to an amorphous structure. The main pharmacokinetic parameters of i.g. administration (crude material and SD) and i.v. route were as follows: Cmax (2.5±1.1), (7.9±3.3), and (6838.7±1322.1) μg/L, tmax (0.7±0.3) and (0.3±0.2) h for the former, AUC0-t (7.1±2.0), (21.0±3.2) and (629.7±111.8) μg·h/L. The absolute bioavailability of native wogonin and wogonin arginine solution were (0.59±0.35)% and (3.65± 2.60)%. Further research showed that the low bioavailability of wogonin might be associated with low solubility and rapid combination with glucuronic acid in vivo. CONCLUSIONS The significantly increased solubility of SDs and the further preparation of arginine solution could significantly increase the bioavailability of wogonin.

Indexed as

AnimalsArginineBiological AvailabilityChemistry, PharmaceuticalDogsDrug CarriersFlavanonesMaleRandom AllocationSolubilityTandem Mass SpectrometryX-Ray DiffractionArginineDrug CarriersFlavanoneswogonin

Identifiers

PMID27744456
PMCPMC5070617
OpenAlexW2530032877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.